Insecticides IndiaQ4 FY24

Insecticides India Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹545.5P/E: 13.0Market Cap: ₹1.6K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Anticipated overall revenue growth up to 10% in B2C segment with volume growth around 20% annually.
  • For FY 25, volume growth guidance is uncertain but expected to remain strong; 20% volume growth in the current year was achieved.
  • Focus on value-added "Maharatna" products growing from 59% to potentially over 65%-75% of sales in next 2-5 years.
  • Expansion from new product launches contributing significantly, with a pipeline of 6-7 new products planned annually.
  • Backward integration and new plant operations at Dahej expected to add approximately INR 100 crores to revenues this fiscal; full year next fiscal estimated INR 300-400 crores.
  • Biological segment to grow steadily but not doubling this year.
  • Exports presently small (~5% of sales), projected to grow modestly by 2-3%.
  • Market share approximated at 5-5.5%, aiming for gradual increase through product innovation and selective portfolio pruning.

See what Insecticides India management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The company has about INR135 crores in Capital Work in Progress (CWIP) related to expansion, especially for the L&T plant at Dahej.
  • No explicit mention of new fundraising through debt or equity in the provided transcript.
  • Expansion plans include backward integration and new product launches, expecting turnover growth from these projects.
  • Delays in plant commissioning (Dahej plant) due to pending government approvals, expected to start operations mid-next quarter.
  • No direct statements about raising funds through debt or equity in the near future were made during the discussions.
  • Focus is on growing turnover and margins from internal operations and product launches rather than external fundraising.

See what Insecticides India management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Capex of approximately INR 100-110 crores is ongoing, primarily for the new L&T plant in Dahej.
  • The Dahej technical plant will start production by mid-next quarter after a 2-3 months delay due to government approvals; expected to contribute INR 300-400 crores turnover next fiscal.
  • Backward integration forms 50% of the Dahej plant's capacity to enhance production and margins.
  • An additional INR 20-25 crores capex is planned for the Sotanala new unit, focusing on formulations and technical development, with production starting around April next year.
  • Sotanala's project timeline is approximately 18 months, with investments spread over the current and next fiscal years.
  • Strategy includes continuous introduction of new generation molecules, mixtures, and focusing on value-added, high-margin proprietary products backed by patents and IPR.

Track Insecticides India — get its next earnings analysis in your feed

How does Insecticides India rank vs peers in Fertilizers & Agrochemicals?

Pro feature
ThisInsecticides India
Rev 3Mar 1

How does Insecticides India rank in Fertilizers & Agrochemicals?

Compare Insecticides India against every Fertilizers & Agrochemicals company (Q4 FY24) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

Others in Fertilizers & Agrochemicals this season

  • Madhya Bharat Agro Products (Q2 FY27)

    Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo

  • Dhansa Labs (Q2 FY27)

    1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Aristo Bio-Tech (Q2 FY27)

    1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu

  • Krishana Phoschem (Q2 FY27)

    Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →